Safety and tolerability of seasonal ultra-rush, high-dose sublingual- swallow immunotherapy in allergic rhinitis to grass and tree pollens: An observational study in 193 children and adolescents

Journal of Investigational Allergology and Clinical Immunology

Volumn 19, Issue 2, 2009, Pages 125-131

  Seidenberg, J ^a,f   Pajno, G Battista ^b   Bauer, C P ^c   La Grutta, S ^d   Sieber, J ^e  

^a Klinik für Pädiatrische Pneumologie und Allergologie Neonatologie und Intensivmedizin Elisabeth Kinderkrankenhaus   (Germany)

^b Clinica Pediatrica   (Italy)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Children's Hospital   (Italy)

^e Stallergenes GmbH   (Germany)

^f KLINIKUM OLDENBURG   (Germany)

Author keywords

Allergic rhinitis; Asthma; Children; Grasses; Safety; Sublingual immunotherapy; Trees; Ultrarush

Indexed keywords

ADRENALIN; AZELASTINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CETIRIZINE; CLEMASTINE; CORTICOSTEROID DERIVATIVE; FLUTICASONE; GRASS POLLEN EXTRACT; LORATADINE; POLLEN EXTRACT; PREDNISOLONE; PREDNISONE; STALORAL; THEOPHYLLINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ALDER; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BIRCH; BURNING SENSATION; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; GASTROENTERITIS; GRASS; GRASS POLLEN; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LIP DISEASE; LIP SWELLING; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL PRURITUS; POLLEN ALLERGY; PRESCHOOL CHILD; PRURITUS; RHINOCONJUNCTIVITIS; SCHOOL CHILD; SUBLINGUAL IMMUNOTHERAPY; TONGUE SWELLING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URTICARIA;

EID: 65249163373     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147-334.
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Ait-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet L-P, Bousquet P-J, Camargos P, Carlsen K-H, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim Y-Y, Kowalski ML, Kuna P, Le LTT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FER, Toskala E, Valovirta E, van Cauwenberge P, Wang D-Y, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Kheder AB, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek J-M, Larenas-Linnemann D, Lipworth B, Malo J-L, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN* and AllerGen*). Allergy. 2008;63(Suppl86):8- 160.
3. Bousquet J, Lockey RF, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997. Allergy. 1998;53(44 Suppl):1-42.
4. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005;60:4-12.
5. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, Canonica GW. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006;97:141-8.
6. Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy. 2005;35:565-71.
7. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr). 1995;23:224-30.
8. Voltolini S, Modena P, Minale P, Bignardi D, Troise C, Puccinelli P, Parmiani S. Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol (Madr). 2001;29:103-10.
9. Vervloet D, Birnbaum J, Laurent P, Hugues B, Fardeau MF, Massabie-Bouchat YP, Aferiat-Derome A, Andre C. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double- blind, placebo-controlled study. Int Arch Allergy Immunol. 2007;142:239-46.
10. Gammeri E, Arena A, D'Anneo R, La Grutta S. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol (Madr). 2005;33:221-23.
11. Tripodi S, Di Rienzo Businco A, Benincori N, Scala G, Pingitore G. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol. 2006;139:149-52.
12. Clavel R, Bousquet J, André C. Clinical efficacy of sublingual- swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy. 1998;53:493-8.
13. Position paper: Immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy. 1993;48(14 Suppl):7-35.
14. ICH E2A. Clinical safety data management: definitions and standards for expedited reporting. London: European Medicines Agency, CPMP/ICH/377/95, November 1994. Available from: www.emea.europa.eu.
15. André C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol. 2000;121:229-34.
16. Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, André C, Papageorgiou PS. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy. 1998;53:662-72.
17. La Rosa M, Ranno C, André C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual- swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1999;104:425-32.
18. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;1 17:1021-35.
19. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr). 1990;18:277-84.
20. Hirsch T, Sähn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol. 1997;8:21-7.
21. Rolinck-Werninghaus C, Wolf H, Liebke C, Baars JC, Lange J, Kopp MV, Hammermann J, Leupold W, Bartels P, Gruebl A, Bauer CP, Schnitker J, Wahn U, Niggemann B. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy. 2004;59:1285-93.
22. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs. 2003;5:777-81.
23. Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L, Marcucci F, Frati F. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol. 2005;95:254-58.
24. Di Rienzo V, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG, Passalacqua G. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy. 2005;35:560-64.